EBMT 2026 China Voice | Professor Heng Mei: Exploring the Global Frontiers of Cellular Therapy—From In Vivo CAR-T to Technological Innovation

EBMT 2026 China Voice | Professor Heng Mei: Exploring the Global Frontiers of Cellular Therapy—From In Vivo CAR-T to Technological Innovation

At the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2026), held in Madrid, “Cell Therapy Day” emerged as one of the most prominent highlights of the congress. The session brought together leading experts from China, the United States, Germany, and other countries, who shared cutting-edge advances and forward-looking perspectives in cellular immunotherapy. The discussions reflected the rapid and diverse global evolution of this transformative field.
EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, bringing together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy. Key topics included optimization of transplant strategies, infection control, CAR-T therapy, and graft-versus-host disease management.
EAU26 Afternoon Dialogue | Professor Ji-Wei Huang: DISTINCT-I Study Redefines Kidney-Sparing Strategies in High-Risk UTUC with ADC–Immunotherapy Neoadjuvant Approach

EAU26 Afternoon Dialogue | Professor Ji-Wei Huang: DISTINCT-I Study Redefines Kidney-Sparing Strategies in High-Risk UTUC with ADC–Immunotherapy Neoadjuvant Approach

Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy of the urinary system, with high-risk subtypes associated with substantial risks of recurrence, metastasis, and poor prognosis. For decades, radical nephroureterectomy has been the standard treatment for high-risk UTUC. However, this approach inevitably leads to irreversible renal function impairment and may even result in renal failure, significantly compromising long-term quality of life.
ASCO GU Expert Insights | Professor Jeremy Teoh (Yuan-Jin Zhang): En Bloc Resection Redefines the Treatment Paradigm for NMIBC

ASCO GU Expert Insights | Professor Jeremy Teoh (Yuan-Jin Zhang): En Bloc Resection Redefines the Treatment Paradigm for NMIBC

At the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), one of the world’s leading academic platforms in genitourinary oncology, Professor Jeremy Teoh (Yuan-Jin Zhang) and his team from The Chinese University of Hong Kong presented a series of landmark studies on en bloc resection of bladder tumor (ERBT). Backed by high-level evidence, these findings have positioned ERBT at the forefront of innovation in non–muscle-invasive bladder cancer (NMIBC), laying a solid clinical foundation for transforming treatment strategies.
EAU26 | Professor Liang-You Gu: Disitamab Vedotin Plus Immunotherapy Achieves a 1-Year DFS Rate of 97.4%, Opening New Directions for Adjuvant Treatment in High-Risk UTUC

EAU26 | Professor Liang-You Gu: Disitamab Vedotin Plus Immunotherapy Achieves a 1-Year DFS Rate of 97.4%, Opening New Directions for Adjuvant Treatment in High-Risk UTUC

With ongoing advances in research, combinations of targeted therapy and immunotherapy have become the standard first-line treatment for advanced urothelial carcinoma. However, upper tract urothelial carcinoma (UTUC) differs significantly from bladder cancer in terms of anatomical structure, pathological characteristics, prognosis, and recurrence risk. As a result, radical nephroureterectomy (RNU) remains the gold standard for non-metastatic UTUC.
Voices from China at the EBMT Annual Meeting Recipient-Derived (Donor-Chimeric) CAR-T with Multimodal Strategies for Early Relapse After Allo-HSCT 

Voices from China at the EBMT Annual Meeting Recipient-Derived (Donor-Chimeric) CAR-T with Multimodal Strategies for Early Relapse After Allo-HSCT 

At the 52nd EBMT Annual Meeting held in Madrid in March 2026, the team led by Prof. Zhang Yajing presented a novel therapeutic approach targeting one of the most challenging clinical scenarios in hematology—early relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).